Cytokinetics, Incorporated (CYTK) Stock Analysis 2026

This chart shows how CYTK's revenue flows through to profit. As a financial-sector company, CYTK doesn't report a traditional cost-of-revenue/gross-margin split, so the cascade starts from operating expenses and works down to net income — the actual profit shareholders own. A high net margin indicates efficient expense control and capital allocation.

Cytokinetics, Incorporated doesn't carry a meaningful trailing P/E right now, generates $-397.4M in free cash flow, hasn't disclosed a debt/equity ratio, and hasn't disclosed return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Wall Street analysts covering Cytokinetics, Incorporated currently haven't converged on a clear consensus rating, with a mean 12-month price target of $109.90. Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

CYTK is currently in a mixed technical position. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Research and guides that put CYTK’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

In-depth reports on companies operating alongside CYTK — business models, bull and bear cases, and the metrics that matter.